Strategy & Innovation

Sort by Default

Display 15 Products per page

A Hangover Is A Disease, German Court Rules

$131.00

Alcohol-related hangovers are genuine illnesses according to a recent ruling by a high-level German court. HBW looks at the case against a German wellness manufacturer for health claims made for its “anti-hangover” supplements and how deeming hangover’s a disease affects the outcome of the case.
September 2, 2019
Find out more
Made In China Gene Therapy A Father’s Quest To Save Son With UltraRare Condition

$131.00

With a population of 1.3 billion and a large patient pool with rare genetic conditions, China has the potential to be the world’s largest market for rare disease treatments. It is believed, however, that China will need to develop its own gene therapies, given that such imported products will be simply too costly for what is a largely self-pay market. Read about one very determined Chinese father’s journey on two continents to find a research provider with the particular expertise to find a new gene therapy to treat his young son’s very rare condition.
August 5, 2019
Find out more
Amarin CEO: Consumers Have Heard About Omega-3 Heart Benefits ‘Too Long’

$200.00

Amarin’s John Thero says the firm expects a jump in sales for Vascepa from potential label expansion allowing a larger patient groups with lower triglycerides than current label indications. At the same time, he notes competitors fail to show broader cardiovascular risk reduction.
August 2, 2019
Find out more
L’Oréal E-Commerce Growth Approaches 50%: ‘We Are Now Clearly A Digital-First Company’

$131.00

Beauty products leader L’Oréal has enjoyed much success thanks to E-commerce, the Asian market and travel retail continue to fuel gains at L’Oréal, which just posted its strongest first half like for-like growth in more than a decade. Skin care remains a key driver as well, offsetting a global slowdown in makeup that has hit the firm’s US business hardest, with little improvement expected this year. Will all this be enough to make up for sluggish conditions in North America and the US in particular, where more than half of L’Oréal’s sales are in makeup? Read the article to find out what else the company is banking on.
August 2, 2019
Find out more
Cannabis Industry Taking Legal Action Against EU Regulators Over CBD Novel Food Classification

$131.00

In response to the recent controversial European Commission decision to classify products containing cannabidiol (CBD) as “novel foods”, the Cannabis Trades Association UK has begun legal action to challenge the classification. Read more about the controversy and legal proceedings here.
March 20, 2019
Find out more
Reckitt Shaking Up Brain Health Market With Neuriva Dietary Supplement And Mobile App Launch In US

$131.00

Reckitt Benckiser Group PLC is looking to become the leader in the booming brain health segment with its release of Neuriva, a dietary supplement whose main ingredient is coffee berry, and whose efficacy, the company says, is backed by a double-blind clinical study.
February 25, 2019
Find out more
Verseon Playing The Long Game To Level Up Drug Discovery

$200.00

Verseon’s computational drug-discovery platform designs candidates that probably wouldn’t be found with conventional methods, according to CEO Adityo Prakash. Discover why he believes Verseon’s approach is paving the way for next-level drug discovery. Gain insights into his refusal to license Verseon’s technology and learn about the company’s blockchain-based subsidiary, BlockRules.
February 11, 2019
Find out more
Global Biopharma R&D Productivity And Growth Rankings

$200.00

Do trends indicating the decline of R&D productivity amid the biggest names in pharma portend more of the same to come? In Vivo takes a look at the data behind the continuing dip in R&D productivity across pharma and examines what it could mean for the future.
January 16, 2019
Find out more
2018’s Top Biopharma Deal-makers

$131.00

How did biopharma shape up for 2018 in terms of mergers, acquisitions, and other business deals? Explore what transpired during last year for M&A in biopharma, when tax cuts were expected to spur major activity. In Vivo brings you a vital look back at the events of 2018.
January 14, 2019
Find out more
Herbalife Shakes Up Executive Suite Due To CEO’s Earlier Statements On Expenses

$131.00

Herbalife CEO Richard Goudis stepped down from the top spot at the company following the discovery of inappropriate comments he had made prior to becoming CEO. Find out more about the Herbalife shakeup and what it means for the company.
January 8, 2019
Find out more
Luxturna Approved In EU: Novartis Outlines Lessons For Gene Therapy Strategies

$131.00

Novartis/Spark Therapeutics readies the launch of its first-ever gene therapy, thanks to approval from the European Commission. Luxturna marks the start of a new strategy for the Swiss drug giant, as Novartis AG’s Global Head of Product and Portfolio Strategy told Scrip in an exclusive interview.
November 23, 2018
Find out more
Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules

$200.00

On the same day the American Kratom Association published its own standards for safety, the FDA coincidentally released the contents of a warning letter to Avalon Packaging, Inc., a kratom contract manufacturer, citing concerns about the manufacturing process and salmonella contamination.
November 20, 2018
Find out more
116th Congress Could Test Cosmetic Industry’s Commitment To Reg Reform, Preemption Viability

$200.00

With Democrats taking control of the US House of Representatives in the fall of 2018, the future of proposed legislation to update cosmetics industry regulations is hazy, but likely to result in stricter regulations for products sold in the United States.
November 19, 2018
Find out more
Infant Formula Production Stalls On Reckitt Benckiser’s Latest Stumble

$200.00

“Technical problems” interrupted infant formula production at Reckitt Benckiser’s Netherlands plant, resulting in an 8% decrease in 2018 third quarter revenue from Enfamil and other brand formulas, a dip that is expected to have repercussions well into 2019.
November 5, 2018
Find out more
Nail Polishes Contain Undeclared DEHP, Among Other ‘Regrettable Substitutions’ – Study

$200.00

Plasticizer Dibutyl phthalate (DBP) is said to have been phased out of use in nail polishes, but a recent study by Harvard public health researchers wonders what is being used to replace the ingredient, and whether it is any safer than DBP.
October 12, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *